GLUE Monte Rosa Therapeutics, Inc. Loading...

Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
11:40
Aug 03
seedy19tron Biotech trader, L/S
No upside case for GLUE post-NVO
Avoid GLUE post-NVO readouts — author sees no identifiable upside catalyst, expects a slow bleed lower, and explicitly declines to take a position.
GLUE 1ST
MED
10:41
Aug 02
A May MD Biotech investor
Draws a mechanistic distinction between GLUE and Canakinumab.
Draws a mechanistic distinction between GLUE and Canakinumab, implying Canakinumab's target validation does not directly apply to GLUE.
GLUE
LOW
16:52
Jul 27
seedy19tron Biotech trader, L/S
Author expresses positive view on GLUE and is considering initiating a position.
Author expresses positive view on GLUE and is considering initiating a position; no current holding confirmed.
GLUE
LOW

About GLUE Analyst Coverage

Buzzberg tracks GLUE (Monte Rosa Therapeutics, Inc.) across 2 sources. 0 bullish vs 0 bearish calls from 2 analysts. Sentiment: evenly split. 3 total trade ideas tracked. Latest voices: seedy19tron, A May MD.